|Bid||109.10 x 900|
|Ask||112.19 x 900|
|Day's Range||111.24 - 114.58|
|52 Week Range||73.69 - 119.84|
|Beta (3Y Monthly)||0.64|
|PE Ratio (TTM)||257.31|
|Earnings Date||Feb 13, 2019|
|Forward Dividend & Yield||2.25 (1.96%)|
|1y Target Est||115.00|
INDIANAPOLIS, Dec. 14, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced an agreement with Hydra Biosciences to acquire all assets related to Hydra's pre-clinical program of TRPA1 antagonists, part of the Transient Receptor Potential (TRP) family of ion channels, that is currently being studied for the potential treatment of chronic pain syndromes. "At Lilly, we are committed to developing new treatment options for people struggling with chronic pain," said Mark Mintun, M.D., vice president of pain and neurodegeneration research at Lilly. "We are very excited to be transitioning this program into Lilly, given their depth of experience in drug development and commercialization," said Russell Herndon, Hydra Biosciences president and chief executive officer.
Of the 14 analysts covering Ionis Pharmaceuticals (IONS), five have given it “buy” or higher ratings, seven have given it “holds,” and two have given it “sells.”
In the most recent quarter, Ionis Pharmaceuticals’ (IONS) selling, general, and administrative expenses rose YoY (year-over-year) to $68.71 million from $26.79 million. Meanwhile, its R&D (research and development) expenses rose YoY to $95.25 million from $80.21 million due to higher drug development costs.
Ionis Pharmaceuticals’ (IONS) two business segments are Ionis Core and Akcea Therapeutics, in which Ionis holds a 76% stake. In its Core Ionis segment, the company is using its antisense technology to develop a pipeline of best-in-class drugs.
AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.
The big drug stocks are on a strong footing of late. Here are five such picks from the biotech and large-cap pharma space that are expected to do well in 2019 too.
Merck and Co said on Friday it will buy privately held French company Antelliq Group, which makes digital identification products for livestock, for about 2.1 billion euros ($2.37 billion) to bolster its fast-growing animal health business. The move affirms the drugmaker's commitment to the business, which Wall Street analysts have long seen value in separating just as rival drugmakers Eli Lilly and Co and Pfizer Inc did. Pfizer's Zoetis raised $2.2 billion in a 2013 IPO, while Elanco, the former animal health business at Lilly, raised $1.51 billion from an IPO in September.
INDIANAPOLIS and SAN MATEO, Calif., Dec. 14, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and Evidation Health, a health and measurement company that helps innovative life sciences and health care companies understand how everyday behavior and health interact, announced today that they have expanded their collaboration with a multi-year agreement to provide Lilly with global access to Evidation's Andromeda data platform. As a result of this announcement, Lilly scientists and researchers across therapeutic portfolios will have access to Evidation's data platform with the goal of uncovering new ways to measure and understand a patient's health by accessing consented data derived from smartphones, connected sensors, wearables, and even his or her own voice.
In 2018 and 2019, Biogen (BIIB) is expected to generate revenues of $13.31 billion and $13.66 billion, respectively, compared to $12.27 billion in 2017.
Eli Lilly (LLY) signs a deal with AC Immune to jointly develop Morphomer tau aggregation inhibitors, which have the potential to treat Alzheimer's disease (AD) and other neurodegenerative diseases.
INDIANAPOLIS, Dec. 13, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to baricitinib, which is being studied for the treatment of systemic lupus erythematosus (SLE). The Fast Track designation process aims to facilitate the development and expedite the review of new medicines that treat serious conditions and fill unmet medical needs, with the goal of delivering potentially important therapies to patients sooner. "There has been only one new treatment for SLE approved in the U.S. in the past 50 years, and Lilly is excited to be at the forefront of potentially bringing a new treatment option to patients with this chronic, multi-organ autoimmune disease that can cause widespread tissue damage," said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly.
RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 13, 2018 /PRNewswire/ -- The Duke Clinical Research Institute (DCRI) is leading a new clinical study to optimize care for people with type 2 diabetes and cardiovascular disease through evaluation of a multidisciplinary approach at cardiology clinics across the U.S. The research program, COORDINATE-Diabetes (COOrdinating CaRDIology CliNics RAndomized Trial of Interventions to Improve OutcomEs), will be funded by Boehringer Ingelheim and Eli Lilly and Company (LLY). "The public health impact of type 2 diabetes and cardiovascular disease in the U.S. is immense," said Christopher Granger, M.D., professor of medicine in the Division of Cardiology at Duke University and lead researcher for COORDINATE-Diabetes.
(Reuters) - Eli Lilly & Co and AC Immune SA have agreed to jointly develop a potential treatment for Alzheimer's disease. Under the terms of the deal, AC Immune will receive an upfront payment of 80 million ...
U.S. drugmaker Eli Lilly & Co and AC Immune SA have agreed to jointly develop the Swiss biotech's potential treatment for Alzheimer's disease. AC Immune already has such partnerships with Johnson & Johnson and Roche Holding AG. There is a desperate need for a treatment for Alzheimer's disease.
AC Immune to receive an initial upfront payment of CHF80 million and will be eligible for CHF60 million in potential near-term development milestones, up to approximately CHF1.7 billion in other potential development, regulatory and commercial milestones, and low double-digit royalties. Lilly to purchase $50 million note, convertible to equity position in AC Immune. AC Immune SA (ACIU) and Eli Lilly and Company (LLY) today announced that the two companies have signed a license and collaboration agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment of Alzheimer’s disease (AD) and other neurodegenerative diseases.
AC Immune to receive an initial upfront payment of CHF80 million and will be eligible for CHF60 million in potential near-term development milestones, up to approximately CHF1.7 billion in other potential development, regulatory and commercial milestones, and low double-digit royalties. Eli Lilly and Company (LLY) and AC Immune SA (ACIU) today announced that the two companies have signed a license and collaboration agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease (AD) and other neurodegenerative diseases.
How's Seattle Genetics Positioned? For fiscal 2018 and 2019, Seattle Genetics’ gross margins are expected at 88.54% and 88.58%, respectively, as compared with gross margins of 88.78% for fiscal 2017. In comparison, the fiscal 2018 gross margins of peers Amgen (AMGN), Gilead Sciences (GILD), and Eli Lilly & Co (LLY) are expected at 85.83%, 84.81%, and 76.05%, respectively.
Seattle Genetics (SGEN) had generated net investment and other income of $82.22 million in the third quarter of 2017. In the third quarter of 2018, on the other hand, it incurred net investment and other loss of $21.87 million.
How's Seattle Genetics Positioned? Seattle Genetics (SGEN) is a biotechnology company with a focus on developing and bringing to market targeted therapies for cancer. Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.
Bristol-Myers (BMY) enters into a collaboration agreement with Vedanta Biosciences to study Opdivo clubbed with the latter's VE800 for treating patients with advanced or metastatic cancers.